Deutsche Bank AG Lowers Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Deutsche Bank AG is a multinational investment bank and financial services company headquartered in Frankfurt, Germany. The company operates globally and provides a range of financial products and services to individuals, corporations, and governments.

Arcturus Therapeutics Holdings Inc. NASDAQARCT is a biotechnology company that is focused on developing and commercializing gene therapy treatments for various diseases. The company's lead product candidate is ARC-190, which is being developed for the treatment of cystic fibrosis.

In the third quarter of 2021, Deutsche Bank AG decreased its position in shares of Arcturus Therapeutics Holdings Inc. NASDAQARCT by 19.0%. This means that the institutional investor sold 7,160 shares of the biotechnology company's stock during the period, reducing its total holdings to 30,426 shares.

It is important to note that this information is based on Deutsche Bank AG's most recent disclosure with the Securities & Exchange Commission and may be subject to change. Additionally, the reasons for the institutional investor's decision to sell its shares in Arcturus Therapeutics Holdings Inc. NASDAQARCT are not specified in the disclosure.